Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Xolair Up for Review for Pollen Allergy, Taltz for Ankylosing Spondylitis on Oct. 31
October 25, 2019
- Kenporen Pushes for No Health Coverage or Higher Copay for OTC-Like Drugs
October 25, 2019
- Chuikyo Mixed on Integration of Kit Premium into Utility Premiums
October 24, 2019
- Chuikyo Payer Rep Moots Higher Prices for Biosames to Incentivize Biosimilar Development
October 24, 2019
- Chuikyo Snubs Industry Request to Revisit Comparator Criteria in New Drug Pricing
October 24, 2019
- Discussions on PMD Law Amendment Bill Start in Extraordinary Diet
October 24, 2019
- Pharma Industry Seeks Cooperation from LDP Lawmakers on Pricing Challenges
October 23, 2019
- Industry to Politicians: Start Vaccine Discussions before Approval to Eliminate Lag Time
October 21, 2019
- Chuikyo OKs Insurance Coverage for Chugai’s Companion Diagnostic to Rozlytrek
October 21, 2019
- 1 Case of Person-to-Person Transmission of Xofluza-Resistant Flu Virus Confirmed in Japan
October 17, 2019
- MHLW Taking Public Comments on Rx-to-OTC for Mosapride
October 17, 2019
- 1st Topical JAK Inhibitor Up for MHLW Panel Review Oct. 25, Ono’s Cachexia Drug Still Shelved
October 15, 2019
- MHLW Orphan Status Dropped for Actemra, Rifampicin
October 15, 2019
- Less than 40% of Public Aware that Antibacterials Are Ineffective Against Common Cold: Govt Survey
October 15, 2019
- Self-Medication Tax Break Not a Clear-Cut System, Needs More Awareness: LDP Lawmakers
October 11, 2019
- Chuikyo Wary about Further Reduction in Generic Entry Prices
October 10, 2019
- Japan Doctor, Pharmacist Groups Oppose Delisting of OTC-Like Drugs: LDP Taskforce
October 10, 2019
- Chuikyo Positive to Add Sakigake Drugs for PMP Coverage, Nudges Industry to Show Counterproposal for Company Criteria
October 10, 2019
- CEFP Discussions on Reform Timeline Update Get Underway
October 10, 2019
- As HIF-PH Inhibitor Debut Looms, MHLW Eyes New Medical Fee Schedule for Renal Anemia
October 10, 2019
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…